CTOs on the Move

Kimochi Home

www.kimochi-inc.org

 
Kimochi Home is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

A Bay Area Vital Link Inc

A Bay Area Vital Link Inc is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carenet Healthcare Services

Complexity in our healthcare system is standing in the way of people accessing care they need. It`s also driving crippling costs. We utilize our deep expertise in influencing consumer behavior to drive better healthcare decisions, increase quality and decrease costs.

Grembowiec and Associates Inc

Grembowiec and Associates Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amanna Health Institute

Amanna Health Institute is a Alpena, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.